FDA inspection
Sichuan Deebio Pharmaceutical Co., Ltd.: FDA inspection ending Sep 8, 2023
FDA inspection 1219423 · Official Action Indicated (OAI) · Guanghan
Key facts
| Inspection ID | 1219423 |
|---|---|
| Firm | Sichuan Deebio Pharmaceutical Co., Ltd. |
| FEI number | 3011139911 |
| Address | 15 Gaocaocun, Xiaohanzhen Guanghan |
| City | Guanghan |
| Country | China |
| Fiscal year | 2023 |
| Inspection end date | Sep 8, 2023 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 669808 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data